Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Reuters

2025/10/16

<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575229756"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575229756\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575229756?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575229756","market":"fut","top_or_hot":-1,"title":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-16 04:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL96f3s8:1","article_id":"2575229756","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575229756","pubTimestamp":1760559083,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units  under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. publis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KAPA":"Kairos Pharma, Ltd."},"translate_title":"Kairos Pharma宣布为高管和董事提供950,000美元的限制性股票单位和227,500美元的现金奖金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    \n\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}